For patients & caregivers

For adults with extensive-stage small cell lung cancer (ES-SCLC) who have had prior platinum-based chemotherapy[1]

Move forward with IMDELLTRA™

In a study of 99 adult patients with ES-SCLC who had 2 or more prior treatments, 2 in 5 patients (40%) responded to IMDELLTRA™,[2] which means their tumor shrank or disappeared.[3]



Not an actual patient.

Based on 99 patients, of which 2 patients saw their tumor completely disappear, and 38 patients saw their tumor partially shrink by at least 30%.[2,4,5]

Important Considerations: The approval of IMDELLTRA™ in these patients is based on a study that measured the size of tumor shrinkage. Talk to your healthcare provider to see if IMDELLTRA™ is right for you.[2,5]

What is IMDELLTRA™ (tarlatamab-dlle)?

IMDELLTRA™ is a prescription medicine used to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which is cancer that has spread throughout lung or to other parts of the body, **and** who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.

It is not known if IMDELLTRA™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA™?

IMDELLTRA™ may cause serious side effects, including:

Cytokine Release Syndrome (CRS). CRS is common during treatment with IMDELLTRA™ and can also be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:

- fever of 100.4°F (38°C) or higher
- low blood pressure
- tiredness
- fast heartbeat or dizziness
- headache
- shortness of breath or trouble breathing
- nausea and vomiting
- confusion, restlessness, or feeling anxious
- problems with balance and movement, such as trouble walking
- heart, liver, or kidney problems
- unusual bleeding or bleeding that lasts a long time

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

IMDELLTRA™ (tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials

Table of contents

What is small cell lung cancer (SCLC) and how may IMDELLTRA™ help?

Cancer is a disease where cells in the body grow out of control. SCLC is an aggressive type of cancer that starts in the lungs and spreads quickly. When it has spread throughout your lungs or other parts of the body, it is referred to as extensive-stage small cell lung cancer (ES-SCLC).[4]

Cancer may not initially respond to treatment, or it may improve initially after treatment but then relapse.[6] A relapse is when the cancer returns. If either of these happen, there may be other treatment options.[4,6]

IMDELLTRA™ is a treatment option for adults with ES-SCLC called a T-cell engager. It is designed to use your body's immune system to fight SCLC cells.[2]

How does IMDELLTRA™ work?

As a T-cell engager, IMDELLTRA™ fights cancer in 2 different ways:[7]

By fighting SCLC cells in the body[2]

&

By helping the immune system destroy those cancer cells[7]

IMPORTANT SAFETY INFORMATION

Due to the risk of CRS, you will receive IMDELLTRA™ as per the following "step-up dosing schedule":

- The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA™ on Day 1 of your first treatment cycle (Cycle 1).
- You will receive the full treatment dose of IMDELLTRA™ on Day 8 and Day 15 of Cycle 1. You will receive the full treatment dose 1 time every 2 weeks after Day 15 of Cycle 1.
- If your dose of IMDELLTRA™ is delayed for any reason, you may need to repeat the "step-up dosing schedule".
- Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA™, you will be given a medicine to help reduce your risk of CRS. This will be given into your vein by intravenous (IV) infusion. You will also receive IV fluids after each of your Cycle 1 doses of IMDELLTRA™ (on Day 1, Day 8, and Day 15). Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Response is possible with IMDELLTRA™

IMDELLTRA™ was studied in 99 adult patients with extensive-stage small cell lung cancer (ES-SCLC). These adult patients already had 2 or more treatments before receiving IMDELLTRA™.[2]

2 in 5 patients (40%)* responded to IMDELLTRA™,[2] which means that their tumor shrank or disappeared[3]



2 out of 99 patients (2%) had a **complete response (CR).**[2] A CR is when your tumor disappears and cannot be seen on a scan.[8]

38 out of 99 patients (38%) had a **partial response (PR).**[2] A PR is when your tumor shrinks by at least 30%.[5]

*In the study, 40 out of 99 patients (40%) responded to IMDELLTRA™ 10 mg.[2]

To learn more about how IMDELLTRA™ may help, visit IMDELLTRA.com.

IMPORTANT SAFETY INFORMATION

Neurologic Problems. IMDELLTRA™ can cause neurologic problems that can be serious or life-threatening. Neurologic problems may happen days or weeks after you receive IMDELLTRA™. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:

- trouble speaking, memory loss, or personality changes
- confusion, feeling disoriented, slow thinking, or not being able to think clearly
- seizure
- problems with walking, or loss of balance or coordination
- weakness or numbness of your arms or legs
- shaking (tremors)
- headache
- numbness or tingling of your hands or feet
- trouble sleeping
- fainting or loss of consciousness
- feeling like you have no energy

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Side effects

IMDELLTRA™ may cause side effects that can be serious or life-threatening. These include cytokine release syndrome (CRS) and neurologic problems.[1]

Cytokine release syndrome (CRS)

CRS is a condition that happens when your immune system reacts harshly to an immunotherapy.[9] It is common during treatment with IMDELLTRA™ and can also be serious or life-threatening.[1]

Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:[1]

- Fever of 100.4 °F (38 °C) or higher
- Low blood pressure
- Tiredness
- Fast heartbeat or dizziness
- Headache
- Shortness of breath or trouble breathing
- Nausea and vomiting
- Confusion, restlessness, or feeling anxious
- Problems with balance and movement, such as trouble walking
- Heart, liver, or kidney problems
- Unusual bleeding or bleeding that lasts a long time

Because there is a risk of CRS, you will start your IMDELLTRA™ treatment with a step-up dose so your healthcare provider can monitor how you are feeling.[1] **See page 10, "Starting IMDELLTRA™," for details on how you will receive your treatment.**

IMDELLTRA™ (tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials

Neurologic problems

IMDELLTRA™ can cause neurologic problems that can be serious or life-threatening. Neurologic problems may happen days or weeks after you receive IMDELLTRA™. Your healthcare provider may refer you to another healthcare provider who specializes in neurologic problems.[1]

Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:[1]

Trouble speaking, memory loss, or personality changes

Confusion, feeling disoriented, slow thinking, or not being able to think clearly

Seizure

Problems with walking, or loss of balance or coordination

Weakness or numbness of your arms or legs

Shaking (tremors)

Headache

Numbness or tingling of your hands or feet

Trouble sleeping

Fainting or loss of consciousness

Feeling like you have no energy

Because there is a risk of CRS and neurologic problems, your healthcare provider will monitor you **for 22 to 24 hours from the start of the IMDELLTRA™ infusion on Day 1 and Day 8 of Cycle 1 in an appropriate healthcare setting** that can manage these side effects. **You should remain within 1 hour of an appropriate healthcare setting for a total of 48 hours** from the start of your IMDELLTRA™ infusion after your Day 1 and Day 8 of Cycle 1 doses **and be accompanied by a caregiver.**[1]

See page 11, "Starting IMDELLTRA™," for more details about how your healthcare provider will monitor you for side effects before and after IMDELLTRA™ treatment for subsequent cycles and later doses.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA™, as well as other side effects, and treat you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA™. Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA™ if you develop CRS, neurologic problems, or any other side effects that are severe.[1] Please see below and the following pages for additional information on the possible side effects for IMDELLTRA™.

Low blood cell counts (cytopenia)

Decreased blood cell counts are common with IMDELLTRA™ and can also be severe.[1]

IMDELLTRA™ may cause the following low blood cell counts:[1]

- Low white blood cell counts (neutropenia), which can increase your risk for infection
- Low red blood cell counts (anemia), which can cause tiredness and shortness of breath
- Low platelet counts (thrombocytopenia), which can cause bruising or bleeding problems



Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Infections

IMDELLTRA™ can cause serious infections that can be life-threatening and may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment with IMDELLTRA™.[1]

Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with IMDELLTRA™, including:[1]

- Fever of 100.4 °F (38 °C) or higher
- Cough
- Chest pain
- Tiredness
- Shortness of breath
- Painful rash
- Sore throat
- Pain during urination
- Feeling weak or generally unwell

Liver problems

IMDELLTRA™ can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS.[1]

Tell your healthcare provider if you develop any signs or symptoms of liver problems, including:[1]

- Tiredness
- Loss of appetite
- Pain in your right upper stomach area (abdomen)
- Dark urine
- Yellowing of your skin or the white part of your eyes

Allergic reactions

IMDELLTRA™ can cause allergic reactions that can be severe.[1]

Go to the nearest emergency room or get help right away if you develop any signs or symptoms of a severe allergic reaction during treatment with IMDELLTRA™, including:[1]

- Shortness of breath or trouble breathing
- Pain or tightness in your chest and back
- Wheezing
- Coughing
- Feeling lightheaded or dizzy
- Rash

Your healthcare provider will do bloodwork before you start and during treatment with IMDELLTRA™. Your healthcare provider will monitor you for signs or symptoms of these serious side effects during treatment and may temporarily or completely stop treatment with IMDELLTRA™ if you develop certain serious side effects.[1]

Most common side effects

The most common side effects of IMDELLTRA™ also include tiredness, fever, a bad or metallic taste in your mouth, decreased appetite, muscle or bone pain, constipation, and nausea.[1]

These are not all of the possible side effects of IMDELLTRA™. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.[1] You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN).

Please see the IMDELLTRA™ Medication Guide for detailed information about side effects and important information you should know about IMDELLTRA™.

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

What to expect with your treatment


Not an actual patient.

IMDELLTRA™ is given by an intravenous (IV) infusion over 1 hour. This means the medicine goes into your body through a needle placed in a vein[1]

Your IMDELLTRA™ treatment schedule is divided into cycles that are usually 28 days (4 weeks) long[1]



- Your healthcare provider will decide how many treatment cycles you will receive[1]
- The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA™ on Day 1 of your first treatment cycle (Cycle 1)[1]
- You will receive the full treatment dose of IMDELLTRA™ on Day 8 and Day 15 of Cycle 1. You will receive the full treatment dose 1 time every 2 weeks after Day 15 of Cycle 1[1]
- If your dose of IMDELLTRA™ is delayed for any reason, you may need to repeat the "step-up dosing schedule"[1]
- You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA™. Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA™ if you develop CRS, neurologic problems, or any other side effects that are severe[1]

IMPORTANT SAFETY INFORMATION

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA™:

- **For Day 1 and Day 8 of Cycle 1 doses,** your healthcare provider will monitor you **for 22 to 24 hours from the start of the IMDELLTRA™ infusion in an appropriate healthcare setting** that can manage these side effects. **You should remain within 1 hour of an appropriate healthcare setting for a total of 48 hours** from the start of the IMDELLTRA™ infusion after your Day 1 and Day 8 of Cycle 1 doses **and be accompanied by a caregiver.**
- **For Day 15 of Cycle 1 and Cycle 2 doses**, your healthcare provider will observe you **for 6 to 8 hours** after the IMDELLTRA™ infusion.
- **For Cycle 3 and Cycle 4 doses,** your healthcare provider will watch you **for 3 to 4 hours** after the IMDELLTRA™ infusion.
- **For Cycle 5 and later doses,** your healthcare provider will watch you **for 2 hours** after the IMDELLTRA™ infusion.

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

IMDELLTRA™ treatment process

Before receiving IMDELLTRA™, tell your healthcare provider about all of your medical conditions, including if you:[1]

- have an infection
- are pregnant or plan to become pregnant

You should plan to arrive at the healthcare facility each day of your treatment cycles[1]

- On Cycle 1 Day 1, you will receive your step-up dose. Your healthcare provider will monitor how you are feeling after this dose
- On Cycle 1 Day 8, Cycle 1 Day 15, and every two weeks thereafter, you will receive the full IMDELLTRA™ treatment dose. Your healthcare provider will continue to monitor how you are feeling after each dose

PRE

Before receiving your Cycle 1 Day 1 and Day 8 doses of IMDELLTRA™, you will be given a medicine by IV infusion to help reduce your risk of CRS[1]

POST

After each of your Cycle 1 IMDELLTRA™ infusions, you will be given IV fluids[1]

Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses[1]

Due to the risk of serious side effects, like CRS and neurologic problems, your healthcare provider will monitor and watch you during and after each of your IMDELLTRA™ infusions[1]

- **For Day 1 and Day 8 of Cycle 1 doses,** your healthcare provider will monitor you **for 22 to 24 hours from the start of the IMDELLTRA™ infusion in an appropriate healthcare setting** that can manage these side effects[1]
- **For Day 15 of Cycle 1 and Cycle 2 doses,** your healthcare provider will watch you **for 6 to 8 hours** after the IMDELLTRA™ infusion[1]
- **For Cycle 3 and Cycle 4 doses,** your healthcare provider will watch you **for 3 to 4 hours** after the IMDELLTRA™ infusion[1]
- **For Cycle 5 and later doses,** your healthcare provider will watch you **for 2 hours** after the IMDELLTRA™ infusion[1]

You should remain within 1 hour of an appropriate healthcare setting for a total of 48 hours from the start of the IMDELLTRA™ infusion after your Day 1 and Day 8 of Cycle 1 doses, **accompanied by a caregiver**[1]

If you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness during treatment with IMDELLTRA™, **do not** drive or operate heavy or potentially dangerous machinery or do other dangerous activities (including work-related activities) until your signs and symptoms go away.[1]

IMDELLTRA™ (tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials

You may receive treatment with IMDELLTRA™ at different healthcare facilities. These locations may be infusion centers, clinics, or hospitals[2]

Keep these things in mind when moving from one healthcare location to another:

Keep track of your calendar by scheduling the appointment at the new facility before you leave the facility of your current treatment. This helps avoid gaps in care

Think of questions you have for your healthcare provider and healthcare team. This brochure includes a few blank pages to write down questions and notes

Journal or take notes about how you feel each day while you're on IMDELLTRA™. This way, you will stay aware of your side effects and can discuss them with your healthcare provider

Keep the phone numbers of your healthcare team up to date in your phone, or write them down on a piece of paper. Include any friends or family you may want to talk to during your treatment

Carry your wallet card with you so it's easy for healthcare providers to identify what treatment you are receiving. Since it's easy to lose wallet cards, you can take a photo of yours so you have a copy on your phone

IMPORTANT SAFETY INFORMATION

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA™, as well as other side effects, and treat you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA™. Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA™ if you develop CRS, neurologic problems, or any other side effects that are severe.

Before receiving IMDELLTRA™, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- are pregnant or plan to become pregnant. IMDELLTRA™ may harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with IMDELLTRA™.
- You should use an effective form of birth control (contraception) during treatment with IMDELLTRA™, and for 2 months after the last dose of IMDELLTRA™.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with IMDELLTRA™.
- are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA™ passes into your breast milk. Do not breastfeed during treatment with IMDELLTRA™ and for 2 months after the last dose of IMDELLTRA™.

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Supportive resources and community organizations

Remember that there are local and national supportive resources and community organizations that may be helpful to you. They can offer information about small cell lung cancer (SCLC) and provide a place to share your experience or hear about other patients' experiences.

Supportive resources

American Cancer Society
1-800-ACS-2345 (1-800-227-2345)

National Cancer Institute
1-800-4-CANCER (1-800-422-6237)

National Comprehensive Cancer Network® (NCCN®)
1-215-690-0300

Community organizations

Patient Advocate Foundation
1-800-532-5274

Cancer Support Community
1-888-793-WELL (1-888-793-9355)

CancerCare, Inc.
1-800-813-HOPE (1-800-813-4673)

Lung cancer community organizations

GO_2 for Lung Cancer
1-800-298-2436

LUNGevity
1-844-360-5864

LiveLung
1-336-302-7714

Lung Cancer Foundation of America
1-323-741-4713

These third-party resources are being shared for informational purposes only; they do not constitute an endorsement or approval by Amgen of any of the products, services, or opinions of the organization or individual. Amgen bears no responsibility for the accuracy of their content.

Financial Support

We know every patient has unique needs. And we're here to provide financial support information and resources, regardless of your current financial situation or the type of insurance you have.

Learn more about the ways Amgen SupportPlus can help you access your prescribed medication. Visit AmgenSupportPlus.com to learn more.

Amgen® SupportPlus Co-Pay Program

If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible for co-pay programs that can help lower the out-of-pocket costs* of your prescription.

The Amgen SupportPlus Co-Pay Program may help patients with private or commercial insurance lower their out-of-pocket costs.

- Pay as little as **$0* out-of-pocket** for each dose
- Can be applied to deductible, co-insurance, and co-payment*
- No income eligibility requirement

Scan QR code to check your eligibility and sign up today at www.AmgenSupportPlus.com/copay.

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

What if I don't have private or commercial insurance (eg, self-purchased or through an employer)?

Amgen SupportPlus can provide information about independent nonprofit foundations that may be able to help.†

†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit's criteria. Amgen has no control over these programs and provides information as a courtesy only.

Amgen® Patient Navigator

Turn to an Amgen Patient Navigator

A single point of contact for answers about starting your Amgen therapy, navigating your treatment journey, and support to help as you start and stay on therapy as prescribed.

Amgen Patient Navigators can help you:

- Understand what to expect from your treatment journey
- Navigate your treatment journey after you leave the hospital
- Answer questions you may have about additional resources

Visit AmgenSupportPlus.com to learn how an Amgen Patient Navigator can help. Call Amgen SupportPlus at (866) 264-2778, Monday – Friday 9:00 AM – 8:00 PM ET.

The Amgen Patient Navigator is not part of a patient's treatment team and does not provide medical advice or case management services. The Amgen Patient Navigator does not administer Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Wallet card

Keep important contacts and information with you during treatment with IMDELLTRA™. Work with your healthcare provider to fill out your treatment wallet card and carry it with you at all times. Since it's easy to lose wallet cards, you can take a photo of yours so you have a copy on your phone.

IMDELLTRA™ (tarlatamab-dlle) WALLET CARD

THIS PATIENT HAS RECEIVED IMDELLTRA™ (FOR HCP)

Patient name

Date & time of first IMDELLTRA™ infusion

Provider name

Office phone

It is recommended that you carry this card with you at all times and show it to any healthcare provider involved in your care.

Definitions for terms related to IMDELLTRA™

Extensive-stage small cell lung cancer (ES-SCLC):
Extensive-stage means the cancer has spread throughout the lung and/or to other areas of the body.[4]

Chemotherapy:
A treatment that uses drugs to stop the replication of cancer cells, either by killing the cells or by stopping them from dividing. It is often called "chemo."[4]

Cytokine release syndrome (CRS):
A condition that happens when your immune system reacts harshly to an immunotherapy, like IMDELLTRA™.[9]

Immunotherapy:
A type of medicine that uses your body's own immune system to help fight conditions such as cancer.[4]

Infusion:
A method of putting fluids, including drugs, into the bloodstream. It is also called "intravenous infusion."[4]

Intravenous (IV):
A way of giving a drug through a needle into a vein.[4]

Please see additional Important Safety Information, including BOXED WARNINGS, on pages 18–19.

Beginning a new treatment can come with many questions. Your healthcare provider can help make sure you understand and have answers to questions like:

- How does IMDELLTRA™ work?
- What can I expect when receiving IMDELLTRA™?
- What are the side effects of IMDELLTRA™?
- Do I need to go to a hospital or can I receive IMDELLTRA™ at an infusion clinic?
- Do I need to take any other medicines before or after my dose?
- When can I leave the healthcare facility after my dose?
- Do I need to stay near a clinic or hospital after each dose? For how long?

Use the space below for questions and notes as you discuss IMDELLTRA™ with your healthcare provider.

IMDELLTRA™ (tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials

What is IMDELLTRA™ (tarlatamab-dlle)?

IMDELLTRA™ is a prescription medicine used to treat adults with extensive-stage small cell lung cancer (ES-SCLC), which is cancer that has spread throughout lung or to other parts of the body, **and** who have received treatment with chemotherapy that contains platinum, and it did not work or is no longer working.

It is not known if IMDELLTRA™ is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMDELLTRA™?

IMDELLTRA™ may cause serious side effects, including:

Cytokine Release Syndrome (CRS). CRS is common during treatment with IMDELLTRA™ and can also be serious or life-threatening. Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:

- fever of 100.4°F (38°C) or higher
- low blood pressure
- tiredness
- fast heartbeat or dizziness
- headache
- shortness of breath or trouble breathing
- nausea and vomiting
- confusion, restlessness, or feeling anxious
- problems with balance and movement, such as trouble walking
- heart, liver, or kidney problems
- unusual bleeding or bleeding that lasts a long time

Due to the risk of CRS, you will receive IMDELLTRA™ as per the following "step-up dosing schedule":

- The step-up dosing schedule is when you receive a smaller dose of IMDELLTRA™ on Day 1 of your first treatment cycle (Cycle 1).
- You will receive the full treatment dose of IMDELLTRA™ on Day 8 and Day 15 of Cycle 1. You will receive the full treatment dose 1 time every 2 weeks after Day 15 of Cycle 1.
- If your dose of IMDELLTRA™ is delayed for any reason, you may need to repeat the "step-up dosing schedule".
- Before receiving your Day 1 and Day 8 doses of Cycle 1 of IMDELLTRA™, you will be given a medicine to help reduce your risk of CRS. This will be given into your vein by intravenous (IV) infusion. You will also receive IV fluids after each of your Cycle 1 doses of IMDELLTRA™ (on Day 1, Day 8, and Day 15). Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

Neurologic Problems. IMDELLTRA™ can cause neurologic problems that can be serious or life-threatening. Neurologic problems may happen days or weeks after you receive IMDELLTRA™. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Tell your healthcare provider right away if you develop any signs or symptoms of neurologic problems, including:

- trouble speaking, memory loss, or personality changes
- confusion, feeling disoriented, slow thinking, or not being able to think clearly
- seizure
- problems with walking, or loss of balance or coordination
- weakness or numbness of your arms or legs
- shaking (tremors)
- headache
- numbness or tingling of your hands or feet
- trouble sleeping
- fainting or loss of consciousness
- feeling like you have no energy

Due to the risk of CRS and neurologic problems, you will receive the following monitoring during treatment with IMDELLTRA™:

- **For Day 1 and Day 8 of Cycle 1 doses,** your healthcare provider will monitor you **for 22 to 24 hours from the start of the IMDELLTRA™ infusion in an appropriate healthcare setting** that can manage these side effects. **You should remain within 1 hour of an appropriate healthcare setting for a total of 48 hours** from the start of the IMDELLTRA™ infusion after your Day 1 and Day 8 of Cycle 1 doses **and be accompanied by a caregiver.**
- **For Day 15 of Cycle 1 and Cycle 2 doses,** your healthcare provider will observe you **for 6 to 8 hours** after the IMDELLTRA™ infusion.
- **For Cycle 3 and Cycle 4 doses,** your healthcare provider will watch you **for 3 to 4 hours** after the IMDELLTRA™ infusion.
- **For Cycle 5 and later doses,** your healthcare provider will watch you **for 2 hours** after the IMDELLTRA™ infusion.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with IMDELLTRA™, as well as other side effects, and treat you as needed. You may be hospitalized if you develop signs or symptoms of CRS or neurologic problems during treatment with IMDELLTRA™. Your healthcare provider may temporarily stop or completely stop your treatment with IMDELLTRA™ if you develop CRS, neurologic problems, or any other side effects that are severe.

IMPORTANT SAFETY INFORMATION (cont'd)

Before receiving IMDELLTRA™, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- are pregnant or plan to become pregnant. IMDELLTRA™ may harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with IMDELLTRA™.
- You should use an effective form of birth control (contraception) during treatment with IMDELLTRA™, and for 2 months after the last dose of IMDELLTRA™.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with IMDELLTRA™.
- are breastfeeding or plan to breastfeed. It is not known if IMDELLTRA™ passes into your breast milk. Do not breastfeed during treatment with IMDELLTRA™ and for 2 months after the last dose of IMDELLTRA™.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while receiving IMDELLTRA™?

Do not drive, operate heavy or potentially dangerous machinery or do other dangerous activities, including work-related activities, during treatment with IMDELLTRA™ if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems.

What are the possible side effects of IMDELLTRA™?

IMDELLTRA™ may cause serious side effects, including:

Low white blood cell counts (cytopenia). Decreased blood cell counts are common with IMDELLTRA™ and can also be severe. IMDELLTRA™ may cause the following low blood cell counts:

- low white blood cell counts (neutropenia). Low white blood cells can increase your risk for infection.
- low red blood cell counts (anemia). Low red blood cells can cause tiredness and shortness of breath.
- low platelet counts (thrombocytopenia). Low platelet counts can cause bruising or bleeding problems.

Infections. IMDELLTRA™ can cause serious infections that can be life-threatening and may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment with IMDELLTRA™. Tell your healthcare provider right away if you develop any signs or symptoms of infection during treatment with IMDELLTRA™, including: fever of 100.4°F (38°C) or higher; painful rash, cough, sore throat, chest pain, pain during urination, tiredness, feeling weak or generally unwell, shortness of breath.

Liver problems. IMDELLTRA™ can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS. Tell your healthcare provider if you develop any signs or symptoms of liver problems, including: tiredness, dark urine, loss of appetite, yellowing of your skin or the white part of your eyes, pain in your right upper stomach-area (abdomen).

Allergic reactions. IMDELLTRA™ can cause allergic reactions that can be severe. Go to the nearest emergency room or get medical help right away if you develop any signs or symptoms of a severe allergic reaction during treatment with IMDELLTRA™, including: shortness of breath or trouble breathing, coughing, pain or tightness in your chest and back, feeling lightheaded or dizzy, wheezing, rash.

Your healthcare provider will do bloodwork before you start and during treatment with IMDELLTRA™. Your healthcare provider will monitor you for signs or symptoms of these serious side effects during treatment and may temporarily or completely stop treatment with IMDELLTRA™ if you develop certain serious side effects.

The most common side effects of IMDELLTRA™ also include: tiredness, muscle or bone pain, fever, constipation, a bad or metallic taste in your mouth, nausea, decreased appetite.

These are not all the possible side effects of IMDELLTRA™.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see accompanying IMDELLTRA™ full Prescribing Information, including BOXED WARNINGS and Medication Guide.

IMDELLTRA™
(tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials

Support and resources for IMDELLTRA™

Financial Support

We know every patient has unique needs. And we're here to provide financial support information and resources, regardless of your current financial situation or the type of insurance you have.

Amgen® SupportPlus Co-Pay Program

If you have private or commercial insurance that you get from your employer or buy directly from a health insurance company, you may be eligible for co-pay programs that can help lower the out-of-pocket costs* of your prescription.

*Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

Amgen® Patient Navigator

A single point of contact for answers about starting your Amgen therapy, navigating your treatment journey, and support to help as you start and stay on therapy as prescribed.

Amgen Patient Navigators can help you:

- Understand what to expect from your treatment journey
- Navigate your treatment journey after you leave the hospital
- Answer questions you may have about additional resources

Visit AmgenSupportPlus.com to learn how an Amgen Patient Navigator can help.
Call Amgen SupportPlus at (866) 264-2778, Monday – Friday 9:00 AM – 8:00 PM ET.

The Amgen Patient Navigator is not part of a patient's treatment team and does not provide medical advice or case management services. The Amgen Patient Navigator does not administer Amgen medications. Patients should always consult their healthcare provider regarding medical decisions or treatment concerns.

Visit IMDELLTRA.com to learn more

References: 1. IMDELLTRA™ (tarlatamab-dlle) medication guide, Amgen. **2.** IMDELLTRA™ (tarlatamab-dlle) prescribing information, Amgen. **3.** Delgado A, et al. *Am J Cancer Res.* 2021;11:1121-1131. **4.** National Cancer Institute. NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed April 4, 2024. **5.** Aykan NF, et al. *World J Clin Oncol.* 2020;11:53-73. **6.** American Cancer Society. www.cancer.org. Accessed April 4, 2024. **7.** Einsele H, et al. *Cancer.* 2020;126:3192-3201. **8.** Eisenhauer EA, et al. *Eur J Cancer.* 2009;45:228-247. **9.** Shimabukuro-Vornhagen A, et al. *J Immunother Cancer.* 2018;6:56.

AMGEN

IMDELLTRA™ (tarlatamab-dlle) for injection 1 mg & 10 mg single-use vials